Clinical Trials Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.

Total 405 results

Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Tolvaptan in Hyponatremic Cancer Patients

Advanced Cancers

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder

Bipolar I Disorder | Manic Episode

United States, Croatia, Ukraine
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder

Bipolar I Disorder | Manic Episode

Serbia, United States, Bulgaria, Poland
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

Nervous System Diseases | Mental Disorder | Alzheimer's Type | Agitation Associated With Alzheimer's Disease

United States, Germany, France, Bulgaria, Spain, Slovenia, Croatia, Serbia, Russian Federation, Ukraine, Canada, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Irritability Associated With Autism Spectrum Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Active, not recruiting

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Alzheimer's Disease

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

Alzheimer Dementia | Agitation Associated With Alzheimer's Dementia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Withdrawn

Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety

Major Depressive Disorder (MDD)
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Nervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's Type

Spain, United States, Germany, Croatia, Serbia, Russian Federation, Ukraine
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.

Bipolar I Disorder | Acute Mania

United States, Serbia, Bulgaria, Croatia, Poland, Ukraine
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Myeloma

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (Anchor)

Irritability Associated With Autism Spectrum Disorder (ASD)

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

Stress Disorders, Post-Traumatic

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Nervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's Type

France, United States, Bulgaria, Slovenia, United Kingdom, Russian Federation, Ukraine, Finland, Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder (ATLAS)

Bipolar I

United States, France, Romania, Poland, Canada, Hungary, Japan, Korea, Republic of, Malaysia, Taiwan
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

Bipolar I Disorder

United States, Taiwan, Romania, Korea, Republic of, Japan, Poland, Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Germany, Poland, Hungary, Slovakia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

ADHD | Conduct Disorder | Oppositional Defiant Disorder | Autism | Bipolar I Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Terminated

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

Nervous System Diseases | Schizophrenia | Mental Disorder

United States
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

STAT3 Inhibitor for Solid Tumors

Solid Tumor | Advanced Cancer

United States
Dallas VA Medical Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Unknown

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection

Helicobacter Infection

United States
Durham VA Medical Center
Otsuka Pharmaceutical Development and Commercialization, Inc.

Unknown

DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole (DIMES)

Schizophrenia | Major Depressive Disorder | Schizo Affective Disorder | Bi-Polar Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Bill and Melinda Gates Foundation

Active, not recruiting

Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

Pulmonary TB

South Africa
Guido Tricot
Otsuka Pharmaceutical Development & Commercialization, Inc.

Terminated

Busulfan in Multiple Myeloma

Multiple Myeloma
Otsuka Pharmaceutical Development & Commercialization...
Bill and Melinda Gates Foundation

Completed

A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis

Pulmonary TB

South Africa
University of Michigan Rogel Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Trial Of Double Umbilical Cord Blood Transplantation

Hematological Malignancies

United States
University of Michigan Rogel Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Terminated

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Multiple Myeloma | Plasma Cell Leukemia

United States
Maisel, Alan, M.D.
Otsuka Pharmaceutical Development & Commercialization, Inc.; Thermo Fisher...

Unknown

Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE) (ACTIVATE)

Acute Heart Failure
Martha Sajatovic
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

Bipolar Disorder | Medication Adherence | Medication Non Adherence

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; PRA Health Sciences

Completed

A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder

Schizophrenia | Bipolar I Disorder

United States
Seung-Jung Park
Otsuka Pharmaceutical Development & Commercialization, Inc.

Terminated

Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)

Coronary Artery Disease

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...
Sumitomo Pharma Co., Ltd.; Sumitomo Pharma America, Inc.

Recruiting

A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
University of Virginia
Merck Sharp & Dohme LLC; Otsuka Pharmaceutical Development & Commercialization...

Recruiting

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

CTCL | PTCL

United States
National Institute of Allergy and Infectious Diseases...
Otsuka Pharmaceutical Development & Commercialization, Inc.

Recruiting

Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB

HIV Infections | Tuberculosis

Tanzania, India, South Africa, Botswana
Otsuka Pharmaceutical Development & Commercialization...
Center for International Blood and Marrow Transplant Research

Completed

PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients

Lymphoma

United States, Canada
University Health Network, Toronto
Celgene Corporation; Otsuka Pharmaceutical Development & Commercialization,... and other collaborators

Completed

Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance (BuMelMCRN001)

Multiple Myeloma

Canada
Otsuka Pharmaceutical, Inc., Philippines
Otsuka Pharmaceutical Co., Ltd.

Terminated

Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients

Pulmonary Disease, Chronic Obstructive

Philippines
University of Michigan Rogel Cancer Center
Genzyme, a Sanofi Company; Otsuka Pharmaceutical Development & Commercialization...

Completed

Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen (CloBu4)

Acute Myeloblastic Leukemia

United States, Canada
Otsuka Pharmaceutical, Inc., Philippines

Completed

Study on the Efficacy and Safety of Oral Probucol Tablets in Patients With Hyperlipidemia - Post-Marketing Surveillance

Hyperlipidemia
Otsuka Pharmaceutical, Inc., Philippines

Completed

Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines (ASCEND)

Polyneuropathy

Philippines
Otsuka Pharmaceutical, Inc., Philippines

Recruiting

"Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program" (RAISE)

Schizophrenia | Major Depressive Disorder

Philippines
Otsuka Pharmaceutical, Inc., Philippines

Completed

Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy

NSAID Induced Gastropathy

Philippines

Clinical Trials Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations